Renz Justin A
Known title: Chief Financial OfficerCIK: 0001466562
Renz Justin A's purchase track record
Renz Justin A has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/31/2022 | ARDX | $2K | +81.4% | +208.0% | -0.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 7,037 | $42K | 8/21/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,218 | $29K | 5/20/2025 | View on chart |
| ARDX | ▲ Buy | Grant | 136,680 | $0 | 2/25/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,171 | $29K | 2/20/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,260 | $25K | 11/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,289 | $31K | 8/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,167 | $40K | 5/21/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,341 | $47K | 2/20/2024 | View on chart |
| ARDX | ▲ Buy | Grant | 127,750 | $0 | 1/16/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 75,000 | $74K | 12/26/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 225,000 | $1.4M | 12/26/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,873 | $13K | 11/20/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,884 | $10K | 8/21/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,873 | $10K | 5/23/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,439 | $10K | 2/21/2023 | View on chart |
| ARDX | ▲ Buy | Grant | 78,000 | $0 | 1/5/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 61 | $118 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,443 | $3K | 11/22/2022 | View on chart |
| ARDX | ▲ Buy | Open Market | 3,000 | $2K | 8/31/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,480 | $1K | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 6 | $6 | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 12 | $12 | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 71,794 | $47K | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,518 | $965 | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,528 | $1K | 5/20/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,800 | $1K | 2/22/2022 | View on chart |
| ARDX | ▲ Buy | Grant | 42,000 | $0 | 1/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 643 | $638 | 11/22/2021 | View on chart |
| ARDX | ▲ Buy | Grant | 250,000 | $0 | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.